Human Immunodeficiency Virus Infection
19
0
0
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
10.5%
2 terminated out of 19 trials
86.7%
+0.2% vs benchmark
26%
5 trials in Phase 3/4
69%
9 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (19)
Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men
HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population
Awareness of Osteoporosis in HIV Patients
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program
Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults
The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)